nach oben

Die Ophthalmologie

Erschienen in:

01.08.2014 | Stellungnahmen und Empfehlungen

Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands zur intravitrealen Therapie des Makulaödems bei Uveitis

Stand: 02.07.2014

verfasst von: Prof. Dr. A. Heiligenhaus, B. Bertram, C. Heinz, L. Krause, U. Pleyer, J. Roider, S. Sauer, S. Thurau

Erschienen in: Die Ophthalmologie | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Auszug

Das Makulaödem ist einer der Hauptgründe für eine Sehverschlechterung bei einer Uveitis. Heutzutage kann mit adäquater Behandlung oftmals ein guter Visus erhalten werden [45, 72]. …

Acharya NR, Hong KC, Lee SM (2009) Ranibizumab for refractory uveitis-related macular edema. Am J Ophthalmol 148:303–309PubMedCrossRef

Adan A, Pelegrin L, Rey A et al (2013) Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients. Retina 33:1435–1440PubMedCrossRef

Alpsoy E, Durusoy C, Yilmaz E et al (2002) Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 138:467–471PubMedCrossRef

Androudi S, Tsironi E, Kalogeropoulos C et al (2010) Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology 117:1612–1616PubMedCrossRef

Angunawela RI, Heatley CJ, Williamson TH et al (2005) Intravitreal triamcinalone acetonide for refractory uveitic cystoid macular oedema: longterm management and outcome. Acta Ophthalmol Scand 83:595–599PubMedCrossRef

Antonetti DA, Barber AJ, Hollinger LA et al (1999) Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 274:23463–23467PubMedCrossRef

Arcinue CA, Ceron OM, Foster CS (2013) A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther 29:501–507PubMedCrossRef

Bae JH, Lee CS, Lee SC (2011) Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. Retina 31:111–118PubMedCrossRef

Bashshur ZF, Ma’luf RN, Allam S et al (2004) Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch Ophthalmol 122:1137–1140PubMedCrossRef

10.

Becker M, Davis J (2005) Vitrectomy in the treatment of uveitis. Am J Ophthalmol 140:1096–1105PubMedCrossRef

11.

Breitbach M, Rack D, Dietzel M et al (2012) Dexamethason-Implantation zur Behandlung des therapierefraktären zystoiden Makulaödems bei nichtinfektiöser Uveitis. Ophthalmologe DOG Abstract

12.

Callanan DG, Jaffe GJ, Martin DF et al (2008) Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 126:1191–1201PubMedCrossRef

13.

Cervantes-Castaneda RA, Giuliari GP, Gallagher MJ et al (2009) Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up. Eur J Ophthalmol 19:622–629PubMed

14.

Chu YK, Chung EJ, Kwon OW et al (2008) Objective evaluation of cataract progression associated with a high dose intravitreal triamcinolone injection. Eye (Lond) 22:895–899

15.

Cordero Coma M, Sobrin L, Onal S et al (2007) Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 114:1574–1579CrossRef

16.

Deuter CM, Kotter I, Gunaydin I et al (2009) Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol 93:906–913PubMedCrossRef

17.

Dugel PU, Rao NA, Ozler S et al (1992) Pars plana vitrectomy for intraocular inflammation-related cystoid macular edema unresponsive to corticosteroids. A preliminary study. Ophthalmology 99:1535–1541PubMedCrossRef

18.

Eckardt C, Bacskulin A (1992) Vitrectomy in intermediate uveitis. Dev Ophthalmol 23:232–238PubMed

19.

Erb C, Schlote T (2011) Medikamentöse Augentherapie

20.

Farvardin M, Afarid M, Mehryar M, Hosseini H (2010) Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina 30:1530–1535PubMedCrossRef

21.

Ferrante P, Ramsey A, Bunce C, Lightman S (2004) Clinical trial to compare efficacy and side effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methyprednisolone in the management of posterior uveitis. Clin Exp Ophthalmol 32:563–568CrossRef

22.

Feucht M, Sturm V, Weissmann J et al (2007) Uveitic cystoid macular edema: intravitreal triamcinolone. Klin Monbl Augenheilkd 224:62–65PubMedCrossRef

23.

Gulati N, Forooghian F, Lieberman R, Jabs DA (2011) Vascular endothelial growth factor inhibition in uveitis: a systematic review. Br J Ophthalmol 95:162–165PubMedCrossRef

24.

Gutfleisch M, Spital G, Mingels A et al (2007) Pars plana vitrectomy with intravitreal triamcinolone: effect on uveitic cystoid macular oedema and treatment limitations. Br J Ophthalmol 91:345–348PubMedCentralPubMedCrossRef

25.

Habot-Wilner Z, Sallam A, Pacheco PA et al (2011) Intravitreal triamcinolone acetonide as adjunctive treatment with systemic therapy for uveitis macular edema. Eur J Ophthalmol 21:56–61CrossRef

26.

Haller JA, Dugel P, Weinberg DV et al (2009) Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina 29:46–51PubMedCrossRef

27.

Hansen LL, Danisevskis P, Arntz HR et al (1985) A randomised prospective study on treatment of central retinal vein occlusion by isovolaemic haemodilution and photocoagulation. Br J Ophthalmol 69:108–116PubMedCentralPubMedCrossRef

28.

Hardman JG, Limbird LE (1996) The pharmacological basis of therapeutics. McGraw-Hill, New York

29.

Hogewind BF, Zijlstra C, Klevering BJ, Hoyng CB (2008) Intravitreal triamcinolone for the treatment of refractory macular edema in idiopathic intermediate or posterior uveitis. Eur J Ophthalmol 18:429–434PubMed

30.

Ip MS, Scott IU, VanVeldhuisen PC et al (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 127:1101–1114PubMedCentralPubMedCrossRef

31.

Jaissle GB, Szurman P, Volker M et al (2007) Epiretinal deposit of triamcinolone acetonide at the posterior pole after intravitreal injection. Ophthalmic Surg Lasers Imaging 38:238–241PubMed

32.

Kempen JH, Altaweel MM, Holbrook JT et al (2011) Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology 118:1916–1926PubMedCentralPubMedCrossRef

33.

Kiryu J, Kita M, Tanabe T et al (2001) Pars plana vitrectomy for cystoid macular edema secondary to sarcoid uveitis. Ophthalmology 108:1140–1144PubMedCrossRef

34.

Kiss S, Wessel MW (2012) Multiple treatments of the sustained release dexamethasone implant for the treatment of posterior non-infectious uveitis. Invest Ophthalmol Vis Sci ARVO Abstract 1185

35.

Kok H, Lau C, Maycock N et al (2005) Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 112:1916PubMedCrossRef

36.

Kotter I, Gunaydin I, Zierhut M, Stubiger N (2004) The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum 33:320–335PubMedCrossRef

37.

Krause L, Altenburg A, Pleyer U et al (2008) Longterm visual prognosis of patients with ocular Adamantiades-Behcet’s disease treated with interferon-alpha-2a. J Rheumatol 35:896–903PubMed

38.

Kube T, Sutter M, Trittler R et al (2006) Carboxymethylcellulose as a new carrier substance for intravitreal injection of reproducible amounts of triamcinolone. Graefes Arch Clin Exp Ophthalmol 244:1385–1390PubMedCrossRef

39.

Kuppermann BD, Blumenkranz MS, Haller JA et al (2007) Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 125:309–317PubMedCrossRef

40.

Ladas ID, Karagiannis DA, Rouvas AA et al (2009) Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina 29:313–318PubMedCrossRef

41.

Landa G, Amde W, Doshi V et al (2009) Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration. Ophthalmologica 223:370–375PubMedCrossRef

42.

Lasave AF, Zeballos DG, El-Haig WM et al (2009) Short-term results of a single intravitreal bevacizumab (avastin) injection versus a single intravitreal triamcinolone acetonide (kenacort) injection for the management of refractory noninfectious uveitic cystoid macular edema. Ocul Immunol Inflamm 17:423–430PubMedCrossRef

43.

Lashay AR, Rahimi A, Chams H et al (2003) Evaluation of the effect of acetazolamide on cystoid macular oedema in patients with Behcet’s disease. Eye (Lond) 17:762–766

44.

Leder HA, Jabs DA, Galor A et al (2011) Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis. Am J Ophthalmol 152:441–448PubMedCrossRef

45.

Levin MH, Pistilli M, Daniel E et al (2014) Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema. Ophthalmology 121:588–595PubMedCrossRef

46.

Lott MN, Schiffman JC, Davis JL (2009) Bevacizumab in inflammatory eye disease. Am J Ophthalmol 148:711–717PubMedCentralPubMedCrossRef

47.

Lowder C, Belfort R Jr, Lightman S et al (2011) Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 129:545–553PubMedCrossRef

48.

Luke M, Januschowski K, Beutel J et al (2008) The effects of triamcinolone crystals on retinal function in a model of isolated perfused vertebrate retina. Exp Eye Res 87:22–29PubMedCrossRef

49.

Maca SM, Abela-Formanek C, Kiss CG et al (2009) Intravitreal triamcinolone for persistent cystoid macular oedema in eyes with quiescent uveitis. Clin Experiment Ophthalmol 37:389–396PubMedCrossRef

50.

Mackensen F, Heinz C, Becker MD, Heiligenhaus A (2008) Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina 28:41–45PubMedCrossRef

51.

Mackensen F, Jakob E, Springer C et al (2013) Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial. Am J Ophthalmol 156:478–486PubMedCrossRef

52.

Miserocchi E, Modorati G, Pastore MR, Bandello F (2012) Dexamethasone intravitreal implant: an effective adjunctive treatment for recalcitrant noninfectious uveitis. Ophthalmologica 228:229–233PubMedCrossRef

53.

Moldow B, Sander B, Larsen M et al (1998) The effect of acetazolamide on passive and active transport of fluorescein across the blood-retina barrier in retinitis pigmentosa complicated by macular oedema. Graefes Arch Clin Exp Ophthalmol 236:881–889PubMedCrossRef

54.

Morrison VL, Kozak I, LaBree LD et al (2007) Intravitreal triamcinolone acetonide for the treatment of immune recovery uveitis macular edema. Ophthalmology 114:334–339PubMedCrossRef

55.

Myong JS, Aaker GD, Kiss S (2010) Treatment of noninfectious posterior uveitis with dexamethason intravitreal implant. Clin Ophthalmol 6:1423–1426

56.

Nehme A, Edelman J (2008) Dexamethasone inhibits high glucose-, TNF-alpha-, and IL-1beta-induced secretion of inflammatory and angiogenic mediators from retinal microvascular pericytes. Invest Ophthalmol Vis Sci 49:2030–2038PubMedCrossRef

57.

Pavesio C, Zierhut M, Bairi K et al (2010) Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 117:567–575PubMedCrossRef

58.

Pleyer U, Klamann M, Winterhalter S et al (o J) Ozurdex: a new therapeutic option in uveitis – clinical outcome from two German centers. Invest Ophthalmol Vis Sci ARVO Abstract 2249

59.

o A (2007) Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration. Klin Monatsbl Augenheilkd 224:559–566CrossRef

60.

Radetzky S, Walter P, Fauser S et al (2004) Visual outcome of patients with macular edema after pars plana vitrectomy and indocyanine green-assisted peeling of the internal limiting membrane. Graefes Arch Clin Exp Ophthalmol 242:273–278PubMedCrossRef

61.

Radwan AE, Arcinue CA, Yang P et al (2013) Bromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edema. Graefes Arch Clin Exp Ophthalmol 251:1801–1806PubMedCrossRef

62.

Roesel M, Gutfleisch M, Heinz C et al (2009) Effect of intravitreal and orbital floor triamcinolone acetonide injection on intraocular inflammation in patients with active non-infectious uveitis. Klin Monbl Augenheilkd 226:110–114PubMedCrossRef

63.

Roesel M, Gutfleisch M, Heinz C et al (2009) Intravitreal and orbital floor triamcinolone acetonide injections in noninfectious uveitis: a comparative study. Ophthalmic Res 42:81–86PubMedCrossRef

64.

Sallam A, Taylor SRJ, Habot-Wilner Z et al (2012) Repeat intravitreal triamcinolone acetonide injections in uveitic macular edema. Acta Ophthalmol 90:e323–e325PubMedCrossRef

65.

Schilling H, Heiligenhaus A, Laube T et al (2005) Long-term effect of acetazolamide treatment of patients with uveitic chronic cystoid macular edema is limited by persisting inflammation. Retina 25:182–188PubMedCrossRef

66.

Scott IU, Ip MS, VanVeldhuisen PC et al (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 127:1115–1128PubMedCentralPubMedCrossRef

67.

Shen L, You Y, Sun S et al (2010) Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application. Ophthalmology 117:2365–2371PubMedCrossRef

68.

Soheilian M, Rabbanikhah Z, Ramezani A et al (2010) Bevacizumab vs. triamcinolone. Ophthalmology 117:855PubMedCrossRef

69.

Soheilian M, Karimi S, Ramezani A et al (2010) Pilot study of intravitreal injection of diclofenac for treatment of macular edema of various etiologies. Retina 30:509–515PubMedCrossRef

70.

Soheilian M, Eskandari A, Ramezani A et al (2013) A pilot study of intravitreal diclofenac versus intravitreal triamcinolone for uveitic cystoid macular edema. Ocul Immunol Inflamm 21:124–129PubMedCrossRef

71.

Taylor SRJ, Banker A, Schlaen A et al (2013) Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis. Retina 33:2149–2154PubMedCrossRef

72.

Thomas ER, Wang J, Ege E et al (2006) Intravitreal triamcinolone acetonide concentration after subtenon injection. Am J Ophthalmol 142:860–861PubMedCrossRef

73.

Tranos PG, Tsaousis KT, Vakalis AN et al (2012) Long-term follow-up of inflammatory cystoid macular edema. Retina 32:1624–1628PubMedCrossRef

74.

Venkatesh P, Abhas Z, Garg S, Vohra R (2007) Prospective optical coherence tomographic evaluation of the efficacy of oral and posterior subtenon corticosteroids in patients with intermediate uveitis. Graefes Arch Clin Exp Ophthalmol 245:59–67PubMedCrossRef

75.

Verbraeken H (1996) Therapeutic pars plana vitrectomy for chronic uveitis: a retrospective study of the long-term results. Graefes Arch Clin Exp Ophthalmol 234:288–293PubMedCrossRef

76.

Weiss K, Steinbrugger I, Weger M et al (2009) Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab. Eye (Lond) 23:1812–1818

77.

Whitcup SM, Csaky KG, Podgor MJ et al (1996) A randomized, masked, cross-over trial of acetazolamide for cystoid macular edema in patients with uveitis. Ophthalmology 103:1054–1062 (discussion 62–63)PubMedCrossRef

78.

Wiechens B, Nolle B, Reichelt JA (2001) Pars-plana vitrectomy in cystoid macular edema associated with intermediate uveitis. Graefes Arch Clin Exp Ophthalmol 239:474–481PubMedCrossRef

79.

Williams GA, Haller JA, Kuppermann BD et al (2009) Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 147:1048–1054PubMedCrossRef

80.

Wilson CA, Berkowitz BA, Sato Y et al (1992) Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 110:1155–1159PubMedCrossRef

Titel: Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands zur intravitrealen Therapie des Makulaödems bei Uveitis
Stand: 02.07.2014
verfasst von: Prof. Dr. A. Heiligenhaus
B. Bertram
C. Heinz
L. Krause
U. Pleyer
J. Roider
S. Sauer
S. Thurau
Publikationsdatum: 01.08.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Die Ophthalmologie / Ausgabe 8/2014
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI: https://doi.org/10.1007/s00347-014-3130-0

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands zur intravitrealen Therapie des Makulaödems bei Uveitis

Stand: 02.07.2014

Auszug

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2014

Okulomotorik und multiple Sklerose

Neue Aspekte in der Therapie der multiplen Sklerose und Optikusneuritis

Aktuelle Empfehlungen zur Neuritis nervi optici

Herausforderungen in der stationären Augenheilkunde bei hoch- und höchstbetagten Patienten

Epiphora bei druckindolenter Schwellung des Augeninnenwinkels

Zunahme der Untersuchungen wegen Katarakt, Glaukom, diabetischer Retinopathie und Makuladegeneration

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde